The FDA released a draft of guidelines for the continuing education of prescribers of long-acting and extended release opioid drugs, according to a Medscape report.
The blueprint, a basic outline and core message the FDA thinks should be conveyed to prescribers, is open to stakeholder comment. The final blueprint will be published to the FDA website for use by providers of continuing education in creating courses for the safe prescribing of opioids.
Related Articles on Opioid:
Opioid Abuse Increasing in Older White Women
Oregon's High Rate of Pain Drug Abuse Linked to Heavy Prescribing
Opioid Pain Reliever Overdose Kills More than Heroin and Cocaine Combined
The blueprint, a basic outline and core message the FDA thinks should be conveyed to prescribers, is open to stakeholder comment. The final blueprint will be published to the FDA website for use by providers of continuing education in creating courses for the safe prescribing of opioids.
Related Articles on Opioid:
Opioid Abuse Increasing in Older White Women
Oregon's High Rate of Pain Drug Abuse Linked to Heavy Prescribing
Opioid Pain Reliever Overdose Kills More than Heroin and Cocaine Combined